John Kirwan

Cook, Inc. develops healthcare devices. The company integrates minimally invasive medical device design, biopharma, gene and cell therapy, and biotech to enhance patient safety as well as improve clinical outcomes in the fields of aortic intervention, interventional cardiology, critical care medicine, gastroenterology, radiology, peripheral vascular, bone access & oncology, surgery and soft tissue repair, urology, and assisted reproductive technology, gynecology as well as high-risk obstetrics. The company is located in Bloomington, IN.

ImmunSYS, Inc. is a clinical stage biopharmaceutical company focused on the development of cancer immunotherapy products. The company was founded by Eamonn P. Hobbs and Charles J. Link Jr. in March 2018 and is headquartered in Fort Lauderdale, FL.

Digital Cognition Technologies, Inc. develops detect presymptomatic cognitive impairment and aid in tracking cognitive devices. The company was founded by Randall S. Davis, Dana L. Penney and Phil A. Cooper in 2015 and is headquartered in Waltham, MA.

Harmonic Medical, Inc. develops non-invasive surgery treatment for uterine fibroids. It also treats broad range of cancer treatment such as bone metastases, metastic liver cancer, hepatocellular carcinoma, thyroid cancer, pancreatic cancer, and kidney cancer. The company is headquartered in Toronto, Canada.

Glens Falls Hospital, Inc. provides health care services. It offers hospital, surgical and community services, and outpatient care centers. The company was founded in 1897 and is headquartered in Glens Falls, NY.

Marvao Medical Devices Ltd. designs develop and markets novel medical devices. It provides products include NexSite 9Fr dual and NexSitetm 8Fr single lumen central venous catheters, as well as NexSite hemodialysis and drainage catheters. The company was founded by Christopher Davey and Mark A. Saab in 2006 and is headquartered in Dublin, Ireland.

E-Z-EM, Inc. develops, manufactures and markets diagnostic imaging products. The firm's products are used for computed tomography and magnetic resonance imaging, colorectal cancer screening, evaluation of swallowing disorders and testing for other diseases, and disorders of the gastrointestinal system. The company was founded in 1961 and is headquartered in Lake Success, NY.

Sentinelle technology is developed by clinicians for clinicians and has evolved over ten years and more than 10000 patient trials. Its products come out of diagnostic imaging research initially conducted at Sunnybrook Health Sciences Centre and the University of Toronto Medical Biophysics department, and continuing over the past three years at Sentinelle. Its ongoing collaboration with academic institutions ensures Sentinelle technology is at the leading edge of the field of breast MRI imaging advances. Sentinelle develops products for General Electric Healthcare, Siemens Medical Solutions and Toshiba Medical Systems. Sentinelle Medical Inc., established in 2004, is a private company based in Toronto, Canada.

The Medical Device Manufacturers Association operates as a trade association. The private company is based in Washington. The American company was founded by Thomas C. Thompson.

The Society of Interventional Radiology is a national organization based in Fairfax, VA, consisting of physicians, scientists, and allied health professionals. The company is dedicated to improving public health through disease management and minimally invasive, image-guided therapeutic interventions.

Syncromune, Inc. is a clinical-stage biopharmaceutical company that is dedicated to developing an in situ platform technology optimized for metastatic solid tumor cancers. The company is based in Fort Lauderdale, FL. The company is currently developing Sync-T™, a novel combination drug/device treatment platform that aims to achieve high response rates with potentially curative efficacy. The therapy is designed to synchronize in situ neoantigen T cell education and immunostimulation via intratumoral/locoregional infusion, with the goal of enabling the immune system to recognize and attack cancer throughout the body. The first two candidates, SV-101 and SV-102, are currently in investigator-initiated phase 1 trials. Link. The company was founded in 2020 by Charles J. Eamonn P. Hobbs has been the CEO of the company since 2020.